Amgen Inc. AMGN NASDAQ

Amgen Inc. (AMGN) reported total assets of $90.59B and total liabilities of $81.93B for fiscal year 2025, resulting in total equity of $8.66B.

The company held $9.13B in cash and short-term investments. Total debt stood at $54.6B, with net debt of $45.48B. The Debt-to-Equity (D/E) ratio was 6.31 (leveraged).

Current ratio is 1.14, suggesting adequate short-term liquidity. Interest coverage is 3.9x (adequate).

Criteria supported by this page:

• HEALTH (33/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
• MOAT (81/100) — Total assets $90.59B and equity $8.66B support the company's competitive scale
• VALUE (33/100) — Debt-to-Equity 6.31 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

MRK

Merck & Co., Inc.

$119.96

-0.16%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%

PFE

Pfizer Inc.

$27.13

-0.77%

BMY

Bristol-Myers Squibb Company

$58.08

+0.03%

BIIB

Biogen Inc.

$178.96

+1.47%